Xin Huang

Dr. Xin Huang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
XHXin Huang
Xin Huang
YZYang Zhou
Yang Zhou
HTHaoze Tang
Haoze Tang
BLBing Liu
Bing Liu
BSBenzhe Su
Benzhe Su
QWQi Wang
Qi Wang

22 May 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
PZPei Zhang
Pei Zhang
QCQiong Chen
Qiong Chen
JLJiahui Lao
Jiahui Lao
JSJuan Shi
Juan Shi
JCJia Cao
Jia Cao
XHXin Huang
Xin Huang
Background: Acute kidney injury (AKI) is a significant concern among hospitalized patients receiving aminoglycosides. Identifying the risk factors associated with aminoglycoside-induced AKI and developing machine learning models are imperative in clinical practice.Objective: This study aims to identify the risk factors associated with AKI in hospitalized patients receiving aminoglycosides, and develop machine learning models for evaluation of the AKI risk in these patients.Methods: This study retrospectively analyzed 7,028 hospitalized patients who received treatment with amikacin or etimicin between 2018 and 2020. According to the type of medication used, patients were divided into amikacin group (n = 307) and etimicin group (n = 6,901). Univariate analyses and the least absolute shrinkage and selection operator algorithm were used to screen risk factors and construct the model. The machine learning models were developed using five different algorithms, including logistic regression (LR), random forest (RF), gradient boosting machine (GBM), extreme gradient boosting model (XGBoost), and light gradient boosting machine (Light GBM).Results: The XGBoost model exhibited the most superior performance in predicting amikacin-associated AKI among the developed machine learning models. For the training set, the area under the receiver-operator characteristic curve (AUC) was 0.916, and for the test set, it was 0.841. The model can be accessed online. Regarding AKI risk in etimicin-treated patients, the GBM model demonstrated the best overall performance, with AUC values of 0.886 for the training set and 0.900 for the test set. The model was also made available online.Conclusion: These predictive models may offer a valuable tool for estimating the risk of AKI in patients receiving amikacin or etimicin, facilitating clinical decision-making and aiding in the prevention of AKI.Trial Registration: ClinicalTrials.gov NCT05533593.

22 November 2023 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
BSBenzhe Su
Benzhe Su
WWWeiwei Wang
Weiwei Wang
XLXiaohui Lin
Xiaohui Lin
SLShenglan Liu
Shenglan Liu
XHXin Huang
Xin Huang
MicroRNAs (miRNAs) play important roles in the occurrence and development of diseases. However, it is still challenging to identify the effective miRNA biomarkers for improving the disease diagnosis and prognosis. In this study, we proposed the miRNA data analysis method based on multi-view miRNA networks and reinforcement learning, miRMarker, to define the potential miRNA disease biomarkers. miRMarker constructs the cooperative regulation network and functional similarity network based on the expression data and known miRNA–disease relations, respectively. The cooperative regulation of miRNAs was evaluated by measuring the changes of relative expression. Natural language processing was introduced for calculating the miRNA functional similarity. Then, miRMarker integrates the multi-view miRNA networks and defines the informative miRNA modules through a reinforcement learning strategy. We compared miRMarker with eight efficient data analysis methods on nine transcriptomics datasets to show its superiority in disease sample discrimination. The comparison results suggested that miRMarker outperformed other data analysis methods in receiver operating characteristic analysis. Furthermore, the defined miRNA modules of miRMarker on colorectal cancer data not only show the excellent performance of cancer sample discrimination but also play significant roles in the cancer-related pathway disturbances. The experimental results indicate that miRMarker can build the robust miRNA interaction network by integrating the multi-view networks. Besides, exploring the miRNA interaction network using reinforcement learning favors defining the important miRNA modules. In summary, miRMarker can be a hopeful tool in biomarker identification for human diseases.

18 December 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XHXin Huang
Xin Huang
BSBenzhe Su
Benzhe Su
MLMengjun Li
Mengjun Li
YZYang Zhou
Yang Zhou
XHXinyu He
Xinyu He
Hepatocellular carcinoma (HCC) is a prevalent malignancy and there is a lack of effective biomarkers for HCC diagnosis. Living organisms are complex, and different omics molecules interact with each other to implement various biological functions. Genomics and metabolomics, which are the top and bottom of systems biology, play an important role in HCC clinical management. Fatty acid metabolism is associated with malignancy, prognosis, and immune phenotype in cancer, which is a potential hallmark in malignant tumors. In this study, the genes and metabolites related to fatty acid metabolism were thoroughly investigated by a dynamic network construction algorithm named EWS-DDA for the early diagnosis and prognosis of HCC. Three gene ratios and eight metabolite ratios were identified by EWS-DDA as potential biomarkers for HCC clinical management. Further analysis using biological analysis, statistical analysis and document validation in the discovery and validation sets suggested that the selected potential biomarkers had great clinical prognostic value and helped to achieve effective early diagnosis of HCC. Experimental results suggested that in-depth evaluation of fatty acid metabolism from different omics viewpoints can facilitate the further understanding of pathological alterations associated with HCC characteristics, improving the performance of early diagnosis and clinical prognosis.

4 December 2017 in IEEE/ACM Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
XLXiaohui Lin
Xiaohui Lin
XHXin Huang
Xin Huang
LZLina Zhou
Lina Zhou
WRWeijie Ren
Weijie Ren
JZJun Zeng
Jun Zeng
XWXingyuan Wang
Xingyuan Wang
Analyzing the disease data from the view of combinatorial features may better characterize the disease phenotype. In this study, a novel method is proposed to construct feature combinations and a classification model (CFC-CM) by mining key feature relationships. CFC-CM iteratively tests for differences in the feature relationship between different groups. To do this, it uses a modified $k$-top-scoring pair ($M-k-TSP$) algorithm and then selects the most discriminative feature pairs in the current feature set to infer the combinatorial features and build the classification model. Compared with support vector machines, random forests, least absolute shrinkage and selection operator, elastic net and $M-k-TSP$, the superior performance of CFC-CM on nine public gene expression datasets validates its potential for more precise identification of complex diseases. Subsequently, CFC-CM was applied to two metabolomics datasets, it obtained accuracy rates of $88.73 \pm 2.06%$ and $79.11 \pm 2.70%$ in distinguishing between hepatocellular carcinoma and hepatic cirrhosis groups and between acute kidney injury (AKI) and non-AKI samples, results superior to those of the other five methods. In summary, the better results of CFC-CM show that in contrast to molecules and combinations constituted by just two features, the combinations inferred by appropriate number of features could better identify the complex diseases.

7 September 2020 in IEEE/ACM Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
XHXin Huang
Xin Huang
ZLZhenqian Liao
Zhenqian Liao
BLBing Liu
Bing Liu
FTFengmei Tao
Fengmei Tao
BSBenzhe Su
Benzhe Su
XLXiaohui Lin
Xiaohui Lin
Different biomarker patterns, such as those of molecular biomarkers and ratio biomarkers, have their own merits in clinical applications. In this study, a novel machine learning method used in biomedical data analysis for constructing classification models by combining different biomarker patterns (CDBP) is proposed. CDBP uses relative expression reversals to measure the discriminative ability of different biomarker patterns, and selects the pattern with the higher score for classifier construction. The decision boundary of CDBP can be characterized in simple and biologically meaningful manners. The CDBP method was compared with eight state-of-the-art methods on eight gene expression datasets to test its performance. CDBP, with fewer features or ratio features, had the highest classification performance. Subsequently, CDBP was employed to extract crucial diagnostic information from a rat hepatocarcinogenesis metabolomics dataset. The potential biomarkers selected by CDBP provided better classification of hepatocellular carcinoma (HCC) and non-HCC stages than previous works in the animal model. The statistical analyses of these potential biomarkers in an independent human dataset confirmed their discriminative abilities of different liver diseases. These experimental results highlight the potential of CDBP for biomarker identification from high-dimensional biomedical datasets and demonstrate that it can be a useful tool for disease classification.